Should autotransplantation in acute myeloid leukemia in first complete remission be revisited?

Current Opinion in Hematology
Tsila ZuckermanJacob Rowe

Abstract

Despite numerous studies, the best postremission therapy in acute myeloid leukemia (AML) is a subject of intense controversy. Major prognostic factors for disease outcome are the genetic alterations of AML, patient's age, and performance status. AML is more common in older adults, with a median age of 72 years. However, in this age group the unfavorable cytogenetics dominates at a time when biologically it may be most difficult to administer optimal intensive therapy. Autologous stem cell transplantation (ASCT) enables the administration of high-dose therapy supported by stem cell infusion with a treatment-related toxicity not significantly higher than that associated with chemotherapy and significantly lower than in allogeneic stem cell transplantation. The dilemma of best postremission therapy has not been resolved because of the paucity of randomized controlled studies, especially in various cytogenetic risk and age groups. Instead, the use of genetic randomization by donor availability, analysis of outcome based on intention-to-treat, and mixed populations in the registry data produce variable results. ASCT has been associated with prolonged disease-free survival as compared to chemotherapy, especially in the favorable and ...Continue Reading

References

Jul 9, 2008·Blood·Jacob M Rowe
Sep 29, 2011·Blood·Edo VellengaUNKNOWN Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Dec 27, 2011·The Lancet Oncology·Markus PfirrmannUNKNOWN Study Alliance Leukaemia (SAL)
May 1, 2012·Bone Marrow Transplantation·J R PasswegUNKNOWN European Group for Blood and Marrow Transplantation (EBMT)
Jun 19, 2012·Bone Marrow Transplantation·J PidalaC Anasetti
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Krzysztof MrózekClara D Bloomfield
Dec 18, 2012·Blood·Stephen J Forman, Jacob M Rowe
Feb 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettNigel Russell
May 2, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·James M ForanDaniel J Weisdorf
Nov 25, 2014·Haematologica·Richard F Schlenk
Feb 1, 2015·Haematologica·Norbert-Claude GorinUNKNOWN Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Jun 27, 2015·Seminars in Hematology·Felix S LichteneggerMarion Subklewe

❮ Previous
Next ❯

Citations

Feb 15, 2017·Bone Marrow Transplantation·V BlumT Pabst
Dec 16, 2017·International Journal of Hematology·Toshihiro MiyamotoUNKNOWN Japan Study Group for Cell Therapy and Transplantation (JSCT)
Dec 1, 2017·Blood Cancer Journal·Sarah BertoliChristian Récher
Dec 1, 2016·International Journal of Hematologic Oncology·Germana CastelliUgo Testa
May 13, 2021·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Katharina KriegsmannPatrick Wuchter

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.